Bicara Therapeutics (NASDAQ:BCAX) Raised to “Strong-Buy” at BMO Capital Markets

Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at BMO Capital Markets to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other research firms have also commented on BCAX. Mizuho lifted their target price on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. The Goldman Sachs Group lifted their price objective on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. BTIG Research increased their target price on Bicara Therapeutics from $28.00 to $39.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Wedbush raised their target price on Bicara Therapeutics from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.64.

Bicara Therapeutics Trading Up 3.8%

Shares of NASDAQ:BCAX opened at $25.86 on Tuesday. Bicara Therapeutics has a 1-year low of $10.30 and a 1-year high of $30.99. The stock has a market capitalization of $1.71 billion, a P/E ratio of -8.34 and a beta of -0.75. The business has a 50-day moving average price of $26.44 and a two-hundred day moving average price of $22.02.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.82). As a group, equities analysts predict that Bicara Therapeutics will post -3.45 EPS for the current year.

Insider Activity

In other Bicara Therapeutics news, CFO Ivan Hyep sold 28,000 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $28.85, for a total value of $807,800.00. Following the completion of the transaction, the chief financial officer directly owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. The trade was a 17.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of the stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total value of $817,641.72. Following the completion of the sale, the chief operating officer owned 182,177 shares of the company’s stock, valued at $5,279,489.46. This trade represents a 13.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 108,000 shares of company stock valued at $3,079,236 in the last quarter. Company insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BCAX. Siren L.L.C. boosted its holdings in shares of Bicara Therapeutics by 11.2% in the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after buying an additional 586,001 shares during the period. Vestal Point Capital LP raised its holdings in shares of Bicara Therapeutics by 2.0% during the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after acquiring an additional 100,000 shares during the period. BlackRock Inc. bought a new stake in Bicara Therapeutics in the 2nd quarter valued at $114,250,000. Janus Henderson Group PLC boosted its stake in Bicara Therapeutics by 26.2% in the 1st quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after purchasing an additional 692,933 shares during the period. Finally, T. Rowe Price Investment Management Inc. increased its holdings in Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after purchasing an additional 2,771,868 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.